TY - JOUR T1 - Angiotensin converting enzyme inhibitors and risk of lung cancer: a population-based cohort study JF - medRxiv DO - 10.1101/2021.01.04.21249217 SP - 2021.01.04.21249217 AU - Joshua Kai Fung Hung AU - Jiandong Zhou AU - Sharen Lee AU - Yunlong Xia AU - Ying Liu AU - Yuhui Zhang AU - Wing Tak Wong AU - Guangling Li AU - Tong Liu AU - Bernard Man Yung Cheung AU - Ian Chi Kei Wong AU - Qingpeng Zhang AU - Gary Tse Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/01/06/2021.01.04.21249217.abstract N2 - Objectives To determine whether the use of angiotensin converting enzyme inhibitors (ACEIs) was associated with a higher risk of lung cancer when compared to use of angiotensin receptor blockers (ARBs).Study Design Population-based cohort study.Setting Public hospitals under the Hospital Authority in Hong Kong, P.R. China.Methods Patients admitted to public hospitals and first prescribed with ACEI and/or ARB between 1 January 2001 and 31 December 2018 were analyzed. The last follow-up date was 31 August 2020, or death, whichever was earlier.Outcomes The primary outcome was the incidence of lung cancer. Logistic regression was used to calculate odds ratio [ORs] with 95% confidence intervals associated with the use of ACEIs compared to ARBs. Incidence and odds ratios were estimated for temporal analysis of incident cancer risk associated with time since the first prescription of ACEI or ARB.Results In the unmatched cohort, 56,697 patients and 357,011 patients were included the ARB and ACEI cohorts, with lung cancer incidence of 2.16% and 1.29%, respectively. Using 1:3 matching for ARB to ACEI users, the incidences were 2.32% and 1.29%. ACEI use was associated with increased risks of lung cancer both before (hazard ratio: 1.30 [1.21-1.40], P<0.0001) and after (1.40 [1.29-1.51], P<0.0001) matching. There was a dose-dependent relationship between ACEI exposure and lung cancer risk.Conclusions ACEI use was associated with increased risk of lung cancer compared with ARB use at all time points. Additionally, incidence risk increases with the duration of exposure.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNoneAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by The Joint Chinese University of Hong Kong - New Territories East Cluster Clinical Research Ethics Committee and Institutional Review Board of the University of Hong Kong/Hospital Authority Hong Kong West Cluster.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.Yes ER -